What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.”In the company’s words, NCT07755904 on ClinicalTrials.gov
Other drugs for Cardiomyopathy, Hypertrophic Obstructive
- SotagliflozinLexicon Pharmaceuticals · Phase 3
- HRS-1893Hengrui · Phase 3
- AficamtenCytokinetics · Phase 2/3
- BAY3723113Bayer · Phase 3
- NinerafaxstatImbria Pharmaceuticals, Inc. · Phase 2
- QG101-23-0Amckaus PTY LTD. · Phase 2
Coming up2
- Oct 2028Phase 3 trial completes · ClinicalTrials.gov
- Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07946107
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Oct 2028 | BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy | |
| Phase 3Not yet recruiting | Dec 2029 | BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026